Acrivon Therapeutics, Inc. (ACRV) Q1 2026 Earnings
ACRV·Reported May 13, 2026·Before market open
Diluted EPS came in at $-0.49 (+3.9% YoY).
Diluted EPS
$-0.49met estimate
Consensus: $-0.49
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Acrivon Therapeutics, Inc.'s Q1 2026 earnings report.
Acrivon Therapeutics, Inc. (ACRV) reported Q1 2026 earnings on May 13, 2026 before market open.
Acrivon Therapeutics, Inc. reported diluted EPS of $-0.49 for Q1 2026.
EPS beat the consensus estimate of $-0.49 by $0.00.
Compared to the same quarter a year prior, diluted EPS grew 3.9% from $-0.51.
You can read the 8-K earnings release (0001193125-26-221626) and the 10-Q periodic report (0001193125-26-221634) directly on SEC EDGAR. The filing index links above go to sec.gov.